Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,718 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Symptom Clusters Clear all
Available No phase listed Expanded access

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

NCT06956547
View directory record Official record
Conditions
Lymphopenia
Interventions
nogapendekin-alfa inbakicept
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 8:37 AM EDT
Active, not recruiting Phase 2 Interventional

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Biological · Procedure · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 8:37 AM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 2 Interventional

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

NCT00000885
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 2, 2026, 8:37 AM EDT
Terminated No phase listed Observational

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

NCT04356443
View directory record Official record
Conditions
Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions
AirGo Respiratory Monitor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 2, 2026, 8:37 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 8:37 AM EDT
Active, not recruiting Not applicable Interventional

Multi-sensory Intervention Room Application (MIRA) Device in the NSICU

NCT06509815
View directory record Official record
Conditions
Post Intensive Care Syndrome
Interventions
MIRA
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 2, 2026, 8:37 AM EDT
Completed No phase listed Observational

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

NCT06734117
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Elecsys® Troponin T hs Gen 6, Blood sample collection
Diagnostic Test · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years and older
Enrollment
5,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
El Centro, California • La Jolla, California • Gainesville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 2, 2026, 8:37 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Nutrition Impact on Tear Film

NCT01561040
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega 3, Vitamins A, D3 and E
Dietary Supplement
Lead sponsor
Eye and Vision Technologies and Research Institute
Network
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Conifer, Colorado • Oak Lawn, Illinois • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Early Phase 1 Interventional

ETCare: Safety and Preliminary Efficacy Trial

NCT01688440
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
#1 Respiratory Care Solution
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Results available

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

NCT04551950
View directory record Official record
Conditions
Cervical Cancer
Interventions
M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 2, 2026, 8:37 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls

NCT05014074
View directory record Official record
Conditions
HIV/AIDS
Interventions
Theater/Pilot Testing
Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 2, 2026, 8:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PAR Regulation of Platelet Function in Diabetic Patients

NCT00855374
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 2, 2026, 8:37 AM EDT
Completed No phase listed Observational

Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men

NCT00919997
View directory record Official record
Conditions
Nonneoplastic Condition, Precancerous Condition
Interventions
DNA analysis, polymerase chain reaction, fluorescence activated cell sorting, questionnaire administration, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 2, 2026, 8:37 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofacial Pain
Interventions
Trigger point injection with 1% lidocaine, Lidocaine patch 5%
Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 8:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

NCT04009148
View directory record Official record
Conditions
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, EPCAM, RAD51C Gene Mutation
Interventions
CASCADE genetic screening
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 2, 2026, 8:37 AM EDT
Recruiting No phase listed Observational

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378
View directory record Official record
Conditions
Chronic Granulomatous Disease (CGD)
Interventions
Not listed
Lead sponsor
Ensoma
Industry
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 8:37 AM EDT
Completed No phase listed Observational

Genetic Regulation of Surfactant Deficiency

NCT00828243
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Nutrient
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 6 Months
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 2, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 2, 2026, 8:37 AM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 2, 2026, 8:37 AM EDT